You have full text access to this OnlineOpen article

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

  1. Peter Grimm1,*,
  2. Ignace Billiet2,
  3. David Bostwick3,
  4. Adam P. Dicker4,
  5. Steven Frank5,
  6. Jos Immerzeel6,
  7. Mira Keyes7,
  8. Patrick Kupelian8,
  9. W. Robert Lee9,
  10. Stefan Machtens10,
  11. Jyoti Mayadev11,
  12. Brian J. Moran12,
  13. Gregory Merrick13,
  14. Jeremy Millar14,
  15. Mack Roach15,
  16. Richard Stock16,
  17. Katsuto Shinohara15,
  18. Mark Scholz17,
  19. Ed Weber18,
  20. Anthony Zietman19,
  21. Michael Zelefsky20,
  22. Jason Wong21,
  23. Stacy Wentworth22,
  24. Robyn Vera23,
  25. Stephen Langley24

Article first published online: 12 JAN 2012

DOI: 10.1111/j.1464-410X.2011.10827.x

Issue

BJU International

BJU International

Special Issue: LDR Brachytherapy: Latest Advances in Prostate Cancer Treatment

Volume 109, Issue Supplement s1, pages 22–29, February 2012

Additional Information

How to Cite

Grimm, P., Billiet, I., Bostwick, D., Dicker, A. P., Frank, S., Immerzeel, J., Keyes, M., Kupelian, P., Lee, W. R., Machtens, S., Mayadev, J., Moran, B. J., Merrick, G., Millar, J., Roach, M., Stock, R., Shinohara, K., Scholz, M., Weber, E., Zietman, A., Zelefsky, M., Wong, J., Wentworth, S., Vera, R. and Langley, S. (2012), Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 109: 22–29. doi: 10.1111/j.1464-410X.2011.10827.x

Author Information

  1. 1

    Prostate Cancer Center of Seattle, WA, USA

  2. 2

    Urology Centre Kortrijk, Belgium

  3. 3

    Bostwick Laboratories, Glen Allen, VA, USA

  4. 4

    Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA

  5. 5

    MD Andersen Center, Houston, TX, USA

  6. 6

    The Prostate Clinic, Utrecht, The Netherlands

  7. 7

    BC Cancer Agency Vancouver Center, Vancouver, BC, Canada

  8. 8

    UCLA, Los Angeles, CA, USA

  9. 9

    Duke University Medical Center, Durham, NC, USA

  10. 10

    Department of Urology, Marien-Krankenhaus, Bergisch Gladbach, Germany

  11. 11

    University of California, Davis, CA, USA

  12. 12

    Chicago Prostate Center, Westmont, IL, USA

  13. 13

    Urologic Research Institute, Wheeling Jesuit University, WV, USA

  14. 14

    Alfred Health and Monash Univeristy, Melbourne, Australia

  15. 15

    University of California, San Francisco, CA, USA

  16. 16

    Mt Sinai Medical Center, New York, USA

  17. 17

    Prostate Cancer Research Institute, Los Angeles, CA, USA

  18. 18

    Prostate Cancer Center of Seattle, WA, USA

  19. 19

    Harvard Medical School, Boston, MA, USA

  20. 20

    Memorial Sloan Kettering Cancer Center, New York, USA

  21. 21

    University of California, Irvine, CA, USA

  22. 22

    Piedmont Radiation Oncology, Greensboro, NC, USA

  23. 23

    Virginia Commonwealth University, Richmond, VA, USA

  24. 24

    Department of Urology, Royal Surrey County Hospital, Guildford, UK

*Dr Peter Grimm, Prostate Cancer Center of Seattle, Seattle, Washington, USA. e-mail: peter@grimm.com

Publication History

  1. Issue published online: 12 JAN 2012
  2. Article first published online: 12 JAN 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (314K)

REFERENCES

  • 1
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–74
  • 2
    Zelefsky MJ, Fuks Z, Hunt M et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Urology 2001; 166: 876–81
  • 3
    National Comprehensive Cancer Network. Prostate Cancer treatment guidelines for patients, 2007. http://www.psa-rising.com/download/nccnguidelines.pdf
  • 4
    Bhatta D, Reuther AM, Zippe C, Klein EA. No difference in 6 year biochemical failure rates with or without pelvic lymph nodes during radical prostatectomy in low-risk patients with prostate cancer. Urology 2004; 63: 528–31
  • 5
    Boorjian S, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the d'Amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179: 1354–61
  • 6
    Kane CJ, Im R, Amling CL et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 2010; 76: 695–700
  • 7
    Kupelian P, Kuban D, Thames H et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25–33
  • 8
    Nguyen PL, Chen MH, Catalona WJ et al. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer: implications for management. Cancer 2008; 113: 3146–52
    Direct Link:
  • 9
    Weight C, Reuther A, Gunn P et al. Limited pelvic lymph node dissection does not improve biochemical relapse free survival at 10 years after radical prostatectomy in patients with low risk prostate cancer. J Urol 2008; 71: 141–5
  • 10
    Menon M, Bhandari M, Gupta N et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol 2010; 58: 838–46
  • 11
    Bittner N, Merrick GS, Galbreath RW et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008; 72: 433–40
  • 12
    Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1315–21
  • 13
    Critz FA, Levinson K. 10-year disease free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation and methodology. J Urol 2004; 172: 2232–8
  • 14
    Hinnen KA, Battermann JJ, van Roermund JG et al. Long-term biochemical and survival outcome of 921 patients treated with I125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 76: 1433–8
  • 15
    Jabbari S, Weinberg VK, Shinohara K et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent seed brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 2010; 76: 36–42
  • 16
    Martin AG, Roy J, Beaulieu L et al. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: a 12-year Canadian experience. Int J Radiat Oncol Biol Phys 2007; 67: 334–41
  • 17
    Merrick GS, Butler WM, Wallner KE et al. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy. Urology 2005; 66: 1048–53
  • 18
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Androgen deprivation therapy does not impact cause-specific overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 65: 669–77
  • 19
    Morris WJ, Keyes M, Palma D et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009; 73: 860–5
  • 20
    Moyad MA, Merrick GS, Butler WM et al. Statins especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005; 66: 1150–4
  • 21
    Pickles T, Keyes M, Morris WJ. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys 2010; 76: 43–9
  • 22
    Potters L, Morgenstern C, Calugaru E et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173: 1562–6
  • 23
    Stone NN, Stock RG, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high bed on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010; 76: 355–60
  • 24
    Taira AV, Merrick GS, Galbreath RW, Wallner KE, Butler WM. Natural history of clinically staged low and intermediate risk prostate cancer treated with monotherapy permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010; 76: 349–54
  • 25
    Zelefsky MJ, Yamada Y, Pei X et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011; 77: 986–90
  • 26
    Zelefsky M, Kuban D, Levy L et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007; 67: 327–33
  • 27
    Zelefsky M, Yamda Y, Cohen, G et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67: 65–70
  • 28
    Demanes DJ, Brandt D, Schour L, Hill DR. Excellent results from high dose rate brachytherapy and external beam prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009; 32: 342–47
  • 29
    Ellis R, Kaminsky DA, Zhou EH et al. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 29–34
  • 30
    Rossi CJ. Conformal proton beam radiation therapy for prostate cancer: concepts and clinical results. Community Oncology 2007; 4: 235–45
  • 31
    Kuban DA, Thames HD, Levy LB et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57: 915–28
  • 32
    Kupelian P, Kuban D, Thames H et al. Improved biochemical relapse-free survival with increased radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005; 61: 415–9
  • 33
    Thames H, Kuban D, DeSilvio M et al. Increasing external beam dose for T1–T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys 2006; 65: 975–81
  • 34
    Zelefsky M, Chan H, Hunt M et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176: 1415–9
  • 35
    Zelefsky M, Yamada Y, Fuks Z et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation in biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 1028–33
  • 36
    Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233–9
  • 37
    Zietman MJ, Yamada Y, Pei X et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95–09. J Clin Oncol 2010; 28: 1106–11
  • 38
    Klein EA, Ciezki J, Kupelian PA, Mahadevan A. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external beam, or brachytherapy. Urol Oncol 2009; 27: 67–71
  • 39
    Vassil AD, Murphy ES, Reddy CA et al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010; 76: 1251–7
  • 40
    Munro NP, Al-Qaisieh B, Bownes P et al. Outcomes for Gleason 7, intermediate risk, localized prostate cancer treated with iodine-125 monotherapy over 10 years. Radiother Oncol 2010; 96: 34–7
  • 41
    Dattoli M, Wallner K, True L, Cash J, Sorace R. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007; 110: 551–5
    Direct Link:
  • 42
    Dattoli M, Wallner K, True L, Bostwick D, Cash J, Sorace R. Long term outcomes for patients with prostate cancer having intermediate and high risk disease, treated with combination external radiation and brachytherapy. J Oncol 2010; 2010: 471375
  • 43
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75: 16–22
  • 44
    Galalae RM, Martinez A, Mate T et al. Long-term outcome by risk factors using conformal high dose brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1048–55
  • 45
    Galalae RM, Martinez A, Nuernberg N et al. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol 2006; 181: 135–41
  • 46
    Phan TP, Syed AM, Puthawala A, Sharma A, Khan F. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 2002; 177: 123–7
  • 47
    Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002; 60: 3–11
  • 48
    Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564–8
  • 49
    Hsu CY, Joniau S, Roskams T, Oyen R, Van Poppel H. Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy. BJU Int 2006; 99: 311–4
    Direct Link:
  • 50
    Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007; 69: 1170–5
  • 51
    Magheli A, Rais-Bahrami S, Peck HJ et al. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. J Urol 2007; 178: 1311–5
  • 52
    Mian BM, Troncoso P, Okihara K et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002; 167: 1675–80
  • 53
    Pierorazio PM, Guzzo TJ, Han M et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimens. Urology 2010; 76: 715–21
  • 54
    Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004; 172: 910–4
  • 55
    Rubio-Briones J, Iborra I, Trassierra M et al. Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy. Actas Urol Esp 2010; 34: 610–7
  • 56
    Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 2000; 471: 129–36
  • 57
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751–6
    Direct Link:
  • 58
    Merrick GS, Butler WM, Galbreath RW et al. Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy. BJU Int 2011; 107: 226–32
    Direct Link:
  • 59
    Merrick GS, Butler WM, Wallner KE et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 61: 32–43
  • 60
    Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009; 104: 1631–6
    Direct Link:
  • 61
    Bittner N, Merrick GS, Wallner KE, Butler WM, Galbreath R, Adamovich E. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer? Int J Radiat Oncol Biol Phys 2010; 76: 1078–84
  • 62
    Kollmeier MA, Stock RG, Stone N. Biochemical outcome after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003; 57: 645–53
  • 63
    Sylvester JE, Grimm PD, Blasko JC et al. 15-year biochemical relapse free survival in clinical stage T1–T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007; 67: 57–64
  • 64
    Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003; 57: 944–52
  • 65
    Deger S, Boehmer D, Türk I et al. High dose rate brachytherapy of localized prostate cancer. Eur Urol 2002; 41: 420–6
  • 66
    Pellizzon AC, Salvajoli JV, Novaes P et al. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 2008; 5: 113–20
  • 67
    Kuban DA, Tucker SL, Dong L et al. Long term results of the MD Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67–74
  • 68
    Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA. Long term outcome following three-dimensional conformal intensity modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008; 53: 1172–9
  • 69
    Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008; 71: 515–8
  • 70
    Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009; 27: 607–612
  • 71
    Nguyen CT, Reuther AM, Stephenson AJ, Klein EA, Jones JS. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol 2009; 181: 75–80
View Full Article (HTML) Get PDF (314K)